US Bio Company CEO Cashes Out $16 Million in Stock as Planned

United Therapeutics Corp. (NASDAQ: UTHR) Chairman and CEO Martine A. Rothblatt exercised roughly 28,000 stock options between April 14 and 16 and sold most of the shares in the open market, generating approximately $16 million in proceeds (about ₩23 billion).

These transactions were automatically executed under a Rule 10b5-1 trading plan adopted in November 2025. After the sale, Rothblatt still retains significant economic exposure through direct ownership of around 40,000 shares, as well as holdings in various family trusts and her spouse’s account.

On April 17, insider Christopher Patusky exercised 1,000 stock options and sold the same number of shares on the open market, raising about $580,000 (roughly ₩800 million) in liquidity while still maintaining a portion of his direct and indirect holdings.

In its May 6 release, United Therapeutics reported first-quarter 2026 earnings per share of $5.82, below the consensus estimate of $7.00. In addition to the financial results, the company is presenting further pulmonary hypertension and organ-transplant pipeline data at major conferences, including the International Society for Heart and Lung Transplantation.

Recently, miroliverELAP—a candidate for treating acute liver failure—received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, marking a regulatory milestone for its regenerative-organ platform.

United Therapeutics is a U.S. biotech company with marketed therapies for rare pulmonary diseases—such as Tyvaso, Remodulin and Orenitram—and focuses on developing and commercializing treatments for chronic, severe conditions both domestically and abroad. Headquartered in Silver Spring, Maryland, and with operations in Research Triangle Park, North Carolina, the company is expanding its portfolio beyond pulmonary vascular diseases into regenerative and transplant-medicine platforms.